Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
115 pending office actions • 67 art units • 107 examiners • 0 of 115 (0%) have an AI response strategy ready • 137 patents granted in the last 365 days
University of Florida Research Foundation Inc. currently manages 109 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 109 actions are distributed across 103 distinct examiners, which indicates a very high degree of individual examiner variety. The involvement of 53 distinct art units further suggests that the company's intellectual property is spread across a wide range of specialized technical groups within the patent office.
The busiest examiner for this portfolio is Johnson, Emily Katharine, who is currently handling 2 of the pending office actions. This small concentration of 2 actions with a single individual means that the vast majority of the portfolio is being reviewed by examiners who are only handling a single case for the entity. For practitioners, this decentralized environment requires a highly adaptable prosecution strategy, as 103 distinct examiners will likely bring a diverse array of perspectives and requirements.
With 53 distinct art units involved, the Biotechnology & Pharmaceuticals filings are subject to many different procedural standards. The 109 pending office actions reflect a broad research and development base that necessitates familiarity with numerous examination units. While Johnson, Emily Katharine and her 2 pending actions represent the busiest point of contact, the overall success of the portfolio depends on navigating the 103 distinct examiners assigned to the various cases.
Based on the USPTO statutory response window for each pending office action. 32 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 32 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 2 (2%) |
| §101 + other | 11 (10%) |
| §103 only | 27 (23%) |
| §102 only | 4 (3%) |
| §112 only | 13 (11%) |
| Double-patenting + other | 14 (12%) |
| Multi-statute (no §101) | 44 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, EMILY KATHARINE | 2 | 87.5% | +21.9% |
| LIPPOLIS, ALEXANDRA ROSE | 2 | 45.7% | +62.4% |
| ROBINSON, HOPE A | 2 | 67.6% | +43.2% |
| KONOPKA, CATHERINE ANNE | 2 | 57.9% | +66.1% |
| KASAYAN, KATRIEL BARCELLANO | 2 | 25.0% | +0.0% |
| NGUYEN, QUANG | 2 | 38.0% | +52.7% |
| CHATTERJEE, JAYANTA | 2 | 41.7% | +68.8% |
| PENNINGTON, KATIE LEIGH | 2 | 31.8% | +58.8% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| MILO, MICHAEL | 1 | 50.8% | +52.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18552486 | PREDICTION OF POST-OPERATIVE PAIN USING HOSVD | STONE, RACHAEL SOJIN | 77d overdue |
| 17772266 | GENE THERAPY VECTORS | PENNINGTON, KATIE LEIGH | 51d overdue |
| 18316064 | DISTRIBUTED LEDGER PLATFORM FOR ELECTRONIC VOTING AND/OR POLLING | LEE, CLAY C | 35d overdue |
| 17802872 | COMPOUNDS THAT MODULATE ANTI-TUMOR IMMUNITY AND METHODS OF DOING THE SAME | HEITMEIER, KENDALL NICOLE | 24d overdue |
| 18191790 | AAV-BASED GENE THERAPY FOR MULTIPLE SCLEROSIS | NGUYEN, QUANG | 9d overdue |
| 16340738 | METHOD AND APPARATUS FOR IMPROVED DETERMINATION OF NODE INFLUENCE IN A NETWORK | LIU, GUOZHEN | 9d overdue |
| 19094455 | SYSTEMS AND METHODS FOR AUTOMATED BUILDING CODE CONFORMANCE | SITTNER, MATTHEW T | 5d overdue |
| 18013954 | EXERGY-BASED LIFE CYCLE ASSESSMENT OF BUILDINGS | YESILDAG, MEHMET | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17772266 | GENE THERAPY VECTORS | PENNINGTON, KATIE LEIGH | 51d overdue |
| 17275399 | SLOW-CYCLING CELL-RNA BASED NANOPARTICLE VACCINE TO TREAT CANCER | PENNINGTON, KATIE LEIGH | 17d overdue |
| 18191790 | AAV-BASED GENE THERAPY FOR MULTIPLE SCLEROSIS | NGUYEN, QUANG | 9d overdue |
| 18114014 | T-DNA Free Gene Editing through Transient Suppressing POLQ in Plants | CHATTERJEE, JAYANTA | 5d overdue |
| 18267144 | METHOD FOR PROGRAMMABLE CONTROL OF RNA TRANSCRIPT LEVELS WITH AUTOREGULATED CRISPR-CAS13D | KONOPKA, CATHERINE ANNE | 20d |
| 18701456 | Insect Toxin Delivery Mediated by a Begomovirus Coat Protein | CHATTERJEE, JAYANTA | 33d |
| 18840617 | Compositions and Methods for Suppression of Flowering in Sugarcane and Energycane | JOHNSON, EMILY KATHARINE | 39d |
| 19682032 | COMPOSITIONS FOR TARGETING MUSCLE CELLS AND USES THEREOF | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1634 | 6 |
| 1662 | 5 |
| 1635 | 5 |
| 1631 | 4 |
| 1636 | 4 |
| 1643 | 3 |
| 1633 | 3 |
| 1637 | 3 |
| 1652 | 3 |
| 1622 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19682032 | COMPOSITIONS FOR TARGETING MUSCLE CELLS AND USES THEREOF | PUTTLITZ, KARL J | 1646 | §103§112 | Non-Final OA | — | Pending | May 19, 2026 |
| 19549567 | CHEST AND ABDOMEN RESTRICTION DEVICE | MILO, MICHAEL | 3786 | §102§103 | Non-Final OA | — | Pending | Feb 25, 2026 |
| 19324860 | VEHICLE SECURITY ANALYSIS PLATFORM | SILVA, MICHAEL THOMAS | 3663 | §103§112 | Non-Final OA | — | Pending | Sep 10, 2025 |
| 19025063 | SYSTEM AND METHOD FOR PERFORMING MULTICAST AUTHENTICATION IN NETWORK-ON-CHIP SYSTEMS | MCFARLAND-BARNES, KELAH JANAE | 2431 | §103 | Final Rejection | — | Pending | Jan 16, 2025 |
| 18874975 | THIAZOLIDINEDIONES FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | INAM, SAHAR | 1622 | §102§112 | Non-Final OA | — | Pending | Dec 13, 2024 |
| 18870030 | CELL-FREE DNA CONCENTRATION IN HYPOTHERMIC MACHINE PERFUSATE AS A RAPID MARKER FOR KIDNEY GRAFT QUALITY | TIWARI, VYOMA SHUBHAM | 1634 | §103§112 | Non-Final OA | — | Pending | Nov 27, 2024 |
| 18865936 | APPARATUS AND METHOD FOR DETERMINING STIMULATION PARAMETERS FOR DEEP BRAIN STIMULATION (DBS) | WEHRHEIM, LINDSEY GAIL | 3799 | §102 | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18912748 | MATERIALS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER | SKOKO III, JOHN JOSEPH | 1643 | §103§112DP | Non-Final OA | — | Pending | Oct 11, 2024 |
| 18904760 | UTILIZATION OF STATIC STRUCTURES IN ADVANCED BUILDING ENVELOPE SYSTEMS TO IMPROVE LIGHTING, THERMAL, ACOUSTIC, AND STORM PROTECTION PERFORMANCE | CHOI, ALICIA M | — | §102§103§112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18884901 | SITE-SPECIFIC INTEGRATING RECOMBINANT AAV VECTORS FOR GENE THERAPY AND IMPROVED PRODUCTION METHODS | JOHNSON, ALLISON MARIE | 1638 | §102§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18842118 | COMBINATORIAL ACTIVATION OF GABA(B) AND A2 ADRENERGIC RECEPTORS PROVIDES RELIEF FROM STRESS INDUCED DEPRESSION | SHAMEEM, GOLAM M | — | §112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18840617 | Compositions and Methods for Suppression of Flowering in Sugarcane and Energycane | JOHNSON, EMILY KATHARINE | 1662 | §103§112 | Final Rejection | 39d | Pending | Aug 22, 2024 |
| 18835859 | SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE | WELLS, LAUREN QUINLAN | 1622 | §102§103§112 | Non-Final OA | — | Pending | Aug 05, 2024 |
| 18728925 | PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §112 | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18720572 | DISCOVERY OF PIPERLONGUMINE AS A NOVEL E3 LIGASE LIGAND | CORNET, JEAN P | 1628 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18716013 | METHOD, APPARATUS, AND SYSTEM FOR REMOVAL OF LESIONS | TEMPLETON, MARINA DELANEY | 3794 | §102§103 | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18706881 | IMPROVED GENETIC TRANSFORMATION BY IMPROVING DE-NOVO SHOOT REGENERATION IN ADULT PLANTS AND DURING IN-VITRO TISSUE CULTURE | JOHNSON, EMILY KATHARINE | 1662 | §102§103§112 | Final Rejection | — | Pending | May 02, 2024 |
| 18706176 | AAV-MEDIATED THERAPIES FOR VISION LOSS ASSOCIATED WITH FRIEDREICH’S ATAXIA | LARA, CAROLINE MONSERRAT | 1633 | §103DP | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18704712 | SMALL MOLECULE DEGRADATION METHODS FOR TREATING ALS/FTD | ROCHELLE, CIERRA MARIE | 1627 | §112DP | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18696085 | GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY | RAHMAN, MASUDUR | 1633 | §102§103 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18693658 | BIOMARKER REFLECTANCE SIGNATURES FOR DISEASE DETECTION AND CLASSIFICATION | KORANG-BEHESHTI, YOSSEF | 2857 | §101§102§103 | Non-Final OA | — | Pending | Mar 20, 2024 |
| 18692493 | AAV PARTICLES WITH MODIFIED INVERTED TERMINAL REPEATS FOR ENHANCED GENE EXPRESSION IN MUSCLE | SMALL, KATHERINE R | 1633 | §102§103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18692438 | AAVRH74 PARTICLES FOR GENE THERAPY OF MUSCLE DISEASE | RYAN, DOUGLAS CHARLES | 1635 | §101§102§103 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18595698 | DYNAMIC REFINEMENT OF HARDWARE ASSERTION CHECKERS | LIN, ARIC | 2851 | §102§103 | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18686633 | RADIATION COMPATIBLE EXPANDER FOR BREAST RECONSTRUCTION | FLORES, ADRIAN | 3774 | §102§103 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18290734 | CONTROLLING PRO-INFLAMMATORY MACROPHAGE PHENOTYPE THROUGH BIOFUNCTIONAL HYDROGEL DESIGN | BEANE, RANDALL L | 1654 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18537160 | SYSTEMS AND METHODS FOR PROVIDING DISTRIBUTED BATTERIES IN INTEGRATED CIRCUITS | DINH, PAUL | — | §102 | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18288301 | SYNTHETIC AAV VECTORS FOR REPEATED DELIVERY OF THERAPEUTIC GENES | KNIGHT, TERESA E | 1634 | §102 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18287711 | AAVRH74 VECTORS FOR GENE THERAPY OF MUSCULAR DYSTROPHIES | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287690 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | BARSKY, JARED | 1628 | §102§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18287368 | AGENTS FOR MANUFACTURE OF CO-ASSEMBLING PEPTIDES | JAUHARI, SACHI | 1654 | §103§112 | Non-Final OA | — | Pending | Oct 18, 2023 |
| 18286453 | COMPOSITIONS AND METHODS FOR TREATING OBESITY | ALDARONDO, DASIA ALI | 1658 | §103§112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18286450 | EXOSOME GENE THERAPY FOR TREATING INNER EAR DISEASE | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103§112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18286046 | ENZYMATIC SYNTHESIS OF MYCOSPORINE-LIKE AMINO ACIDS | RAMIREZ, DELIA M | 1652 | §112Other | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18552486 | PREDICTION OF POST-OPERATIVE PAIN USING HOSVD | STONE, RACHAEL SOJIN | 3681 | §101§103 | Non-Final OA | 77d overdue | Pending | Sep 26, 2023 |
| 18551004 | Methods and kits for targeted cleavage and enrichment of Nucleic Acids for high-throughput analyses of user-defined genomic regions | PHAM, KHAI QUYNH TIEN | 1684 | §103 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18282503 | CHIMERIC PHAGOCYTIC RECEPTORS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | HUYNH, PHUONG N | 1641 | §103§112 | Final Rejection | — | Pending | Sep 15, 2023 |
| 18236078 | PROTEIN-PEG INTERACTIONS THAT REDIRECT THE THERMAL UNFOLDING PATHWAY OF PEGYLATED HUMAN GALECTIN-3C | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18031505 | SELF-ASSEMBLING URICASE FUSION PEPTIDES | MOEHLMAN, ANDREW TERRY | 1655 | §103§112 | Final Rejection | 41d | Pending | Aug 18, 2023 |
| 18451509 | SPATIO-TEMPORAL INTELLIGENT DIGITAL MEMORY SYSTEMS AND METHODS | COLEMAN, PAUL | 2126 | §103 | Final Rejection | — | Pending | Aug 17, 2023 |
| 18271769 | SYNERGISTIC MIXTURES COMPRISING PYRETHRUM FOR ARTHROPOD TOXICITY AND REPELLENCY | MELLER, MICHAEL V | 1655 | §101§102§103 | Final Rejection | — | Pending | Jul 11, 2023 |
| 18271584 | ANTICANCER COMPOUNDS AND USES THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §112 | Final Rejection | — | Pending | Jul 10, 2023 |
| 18267144 | METHOD FOR PROGRAMMABLE CONTROL OF RNA TRANSCRIPT LEVELS WITH AUTOREGULATED CRISPR-CAS13D | KONOPKA, CATHERINE ANNE | 1635 | §103§112 | Final Rejection | 20d | Pending | Jun 14, 2023 |
| 18257237 | DIPHENHYDRAMINE AND LACTOFERRIN FOR PREVENTION AND TREATMENT OF COVID-19 | COFFA, SERGIO | 1658 | §103DP | Final Rejection | 56d | Pending | Jun 13, 2023 |
| 18331891 | DIRECT CONVERSION OF HUMAN MESENCHYMAL STEM CELLS TO HUMAN CARDIOMYOCYTES | KASAYAN, KATRIEL BARCELLANO | 1634 | §112 | Final Rejection | — | Pending | Jun 08, 2023 |
| 18327296 | FUNCTIONAL VERIFICATION FLOW OF OBFUSCATED DESIGNS FOR CIRCUITS | NGUYEN, NHA T | 2851 | §103 | Final Rejection | — | Pending | Jun 01, 2023 |
| 18038321 | USE OF INSULIN-LIKE GROWTH FACTORS WITH GAMMA-CHAIN CYTOKINES TO INDUCE HOMEOSTATIC PROLIFERATION OF LYMPHOCYTES | SULLIVAN, DENNIS JOHN | 1642 | §103 | Non-Final OA | — | Pending | May 23, 2023 |
| 18037364 | MULTIFUNCTION MICROFLUIDIC OPTRODE | ROANE, AARON F | 3796 | §102 | Non-Final OA | — | Pending | May 17, 2023 |
| 18253010 | Modified Insecticidal Proteins | MEADOWS, CHRISTINA L | 1663 | §112 | Final Rejection | 35d overdue | Pending | May 15, 2023 |
| 18316064 | DISTRIBUTED LEDGER PLATFORM FOR ELECTRONIC VOTING AND/OR POLLING | LEE, CLAY C | 3699 | §101§103 | Final Rejection | 35d overdue | Pending | May 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversity of Florida Research Foundation Inc. has 115 pending office actions as of October 2026, spread across 67 art units and 107 examiners.
Emily Katharine Johnson has the most, with 2 of University of Florida Research Foundation Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.